ArticleAdvances in rheumatology (London, England)2025
Comparative analysis of conventional and novel inflammatory biomarkers in Familial Mediterranean fever during attack-free periods.
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the systemic immune-inflammation index (SII) in rheumatic diseases.Frontiers in immunology · 2026Pooled it
- Evidence of the role of Midkine and Pleiotrophin in the pathogenesis of Familial Mediterranean Fever.European journal of pediatrics · 2026Article
- Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial Mediterranean fever (FMF) is a monogenic autoinflammatory condition accompanied with periodic attacks of fever. The clinical utility of some novel inflammatory parameters has not been well explored in FMF. Hence, the aim of this study was to explore the accuracy of a variety of inflammatory indexes in patients with an FMF-attack-free period and without a complication of amyloidosis.
methodsThis cross-sectional study included a total of 114 patients with FMF (of them, 43.8% were men) and 97 controls (of them, 43.3% were men). Complete blood count, albumin, fibrinogen, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA) were measured. Other parameters were calculated [i.e., platelet-albumin ratio (PAR), HALP score, systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV)]. Receiver operating characteristic (ROC) curve analysis was used to test the discriminative ability of each marker between patients with FMF and those without FMF.
resultsThe area under the ROC curve for fibrinogen [AUC = 0.710, 95% CI (0.644-0.770)], CRP [AUC = 0.780 (0.718-0.834)], fibrinogen/albumin [AUC = 0.722 (0.657-0.782)], and CRP/albumin [AUC = 0.782 (0.720-0.836)] indicated satisfactory clinical accuracy. The AUCs for SAA [AUC = 0.844 (0.788-0.890)], SAA/albumin [AUC = 0.856 (0.801-0.900)], and PLT/SAA [AUC = 0.810 (0.750-0.861)] indicated good clinical accuracy. There was no difference between AUCs for SAA and SAA/albumin (P = 0.073), whereas the AUCs for these 2 parameters were significantly higher than the AUC for PLT/SAA (P = 0.033 and P = 0.005, respectively).
conclusionSAA and SAA/albumin ratio are the most reliable biomarkers in discriminating patients with FMF from healthy individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.